NewAmsterdam Pharma N.V.

7 hours ago · globenewswire.com

- First-in-Class approval supported by Phase 3 BROADWAY, BROOKLYN, and TANDEM trials demonstrating significant LDL-C reductions with favorable tolerability profile-

11 days ago · defenseworld.net

NewAmsterdam Pharma (NASDAQ: NAMS - Get Free Report) and Biogen (NASDAQ: BIIB - Get Free Report) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, analyst recommendations, earnings, dividends and profitability. Insider and Institutional Ownership 89.9% of NewAmsterdam Pharma shares

18 days ago · globenewswire.com

NAARDEN, The Netherlands and MIAMI, Sept. 03, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that the Compensation Committee of NewAmsterdam's Board of Directors approved the grant of inducement share options covering an aggregate of 38,900 of NewAmsterdam's ordinary shares to five non-executive new hires, as well as inducement share options covering 14,000 ordinary shares to Robert Gunning, the Company's new Vice President, Controller, who serves as the Company's principal accounting officer. The share options were granted as an inducement material to the employees' acceptance of employment with NewAmsterdam pursuant to the NewAmsterdam Pharma Company N.V. 2024 Inducement Plan (the “2024 Inducement Plan”) and in accordance with Nasdaq Listing Rule 5635(c)(4).

19 days ago · globenewswire.com

NAARDEN, The Netherlands and MIAMI, Sept. 02, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V.

26 days ago · globenewswire.com

NAARDEN, The Netherlands and MIAMI, Aug. 26, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that it will present data from its obicetrapib development program at the European Society of Cardiology (ESC) Congress 2026, taking place August 28 – 31, 2026 in Munich, Germany.

2 months ago · marketbeat.com

NewAmsterdam Pharma NASDAQ: NAMS used its annual Investor Day to outline its cardiovascular outcomes strategy for obicetrapib, provide updates on additional clinical programs and discuss commercial preparations ahead of a potential European launch.

2 months ago · zacks.com

NewAmsterdam Pharma Company N.V. (NAMS) came out with a quarterly loss of $0.52 per share versus the Zacks Consensus Estimate of a loss of $0.48.

2 months ago · globenewswire.com

– Announced positive CHMP opinion recommending marketing authorization for obicetrapib and obicetrapib/ezetimibe – – PREVAIL interim analysis planned for 4Q2026 with result expected in 1Q2027 – – Topline data from RUBENS Phase 3 expected by year-end 2026 – – $678.3 million in cash, cash equivalents and marketable securities at June 30, 2026 – – Company to host investor day today at 9:00 AM ET in New York City – NAARDEN, the Netherlands and MIAMI, Aug. 05, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced financial results for the quarter ended June 30, 2026 and provided a corporate update.

2 months ago · globenewswire.com

NAARDEN, The Netherlands and MIAMI, July 29, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that it will host an Investor Day event for analysts and investors on August 5, 2026 beginning at 9:00 a.m. ET in New York City.

2 months ago · prnewswire.com

/PRNewswire/ -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS oder „NewAmsterdam" oder das „Unternehmen"), ein biopharmazeutisches Unternehmen in der späten